Abolmed

 ABOLmed LLC is a pharmaceutical company, one of the largest pharmaceutical companies in Russia.



The company's headquarters are located inNovosibirsk.


The company was founded in April 1998.  Initially, it was created for the production of antibacterial chemopreparations. The basis of the enterprise then was the production facilities in the cityVidnoye Moscow Region. First batch of products (cephalosporin antibioticNatsef) was released in November 1998.


In the next four years, ABOLmed started producing seven antibiotics-cephalosporins, which were previously imported to Russia.


In 2000, construction of the company's fully automated plant in Novosibirsk was started with a planned capacity of 25 million vials per year.


In 2004, the first stage of the plant was put into operation. The construction cost the owners $20 million, of which about $8 million was provided.International Finance Corporation.


By the end of 2004, the company was producing 10 antibiotics for injection of various groups (including antibiotics that overcome microbial resistance).


In October 2009, the production of antimicrobial drugs in the form of infusion solutions was launched at the company's Novosibirsk plant. About 1 billion rubles were invested in the new production. In 2009, the company's production volume increased by 50 % and amounted to about 2 billion rubles.


In July 2018, the Arbitration Court accepted the claim from the company's creditors and entered bankruptcy proceedings againstit .


Activity

ABOLmed develops, manufactures and distributes pharmaceutical products.


ABOLmed is one of the main suppliers of hospital antibiotics for Russian hospitals. Production volumes of the Novosibirsk branch of ABOLmed in 2009 amounted to 12.5 million vials.


The company produces antimicrobials for the treatment of clinically significant infections: cefazolin, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, cefepime, cefoxitin, fosfomycin, meropenem, imipenem+cilastatin, aztreonam, doxycycline, vancomycin, ofloxacin, pefloxacin, levofloxacin, polymyxin B, metronidazole and others. capreomycin. The latter is used to treat tuberculosis caused by strains of mycobacteria with multiple drug resistance.


In 2010, Abolmed was the only Russian manufacturer of a monobactam antibiotic.


In 2013, the company introduced radio frequency identification (RFID) technology to protect its products from counterfeiting.


Structure and management

ABOLmed has 2 pharmaceutical plants and 19 branches in the regions of Russia.


Fyodor Anokhin has been the company's CEO since 2014.


Commercial Director-Viktor Limonov. He is also the Development Director of Limonov LLC (lessor of production areas and owner of assets of ABOLmed LLC).. Previously, Viktor Limonov held the position of General Director of ABOLmed LLC.


Finance

The company's turnover in 2008 was 1.7 billion rubles, net profit — 64 million rubles.


At the end of April 2010, the company's production volume was about $ 7 million per month.


According to data in the Seldon system.Basis, in 2015, the company's revenue was RUB 230 million (a decrease of RUB 622.55 million). compared to the corresponding indicator of 2014), the net loss decreased and reached 53.32 million rubles (in 2014, the net loss was 82.8 million rubles).

Comments

Popular posts from this blog

Altai State Institute of Culture

Astronomical and Geodetic Association

Archive of Foreign Policy of the Russian Federation